Fact Source: Financial Supervisory Service DART
💡 3-Second Summary
ALTEOGEN will participate in the presentation session at ‘Hankyung Korea Investment Week 2025’ held at the Conrad Seoul Hotel in Yeouido to present its bio-platform technologies and pipeline status/plans to domestic and international investors and the media.
📊 [Key Disclosure Details & Major Figures Summary]
- Event Name: Participation in Hankyung Korea Investment Week 2025 Presentation Session
- Date & Time: September 17, 2025, 13:50 – 14:20
- Location: Grand Ballroom, Conrad Seoul Hotel, Yeouido
- Target Audience: Domestic and international investors, media, etc.
- Purpose: To introduce the company’s core technologies and vision
- Method: Corporate presentation via participation in the event presentation session
- Key Details: ALTEOGEN’s bio-platform technologies, pipeline status, and future plans
- Sponsoring Institution: The Korea Economic Daily (Hankyung)
- Confirmation Date: September 10, 2025
- Contact Department: IR Team (Tel: +82-42-384-8777)
- IR Material Publication: Scheduled for publication on September 17, 2025, on the KRX KIND system website (http://kind.krx.co.kr)
📝 Editor’s Comment (Key Follow-up Checkpoint)
📌 Verification of Platform Technologies and Pipeline Status via Published IR Materials
The company plans to publish its IR presentation materials on the KRX KIND system on September 17, 2025, for this event. Reviewing the official presentation materials provided to investors and the media is essential because it allows investors to verify the progress of core platform technologies and pipeline strategic directions. Detailed contents can be cross-checked in the official IR presentation materials published on the KRX KIND system website.
📢 Disclaimer & Source Notice
Source: This content has been structured and newly created based on official filing data from the Financial Supervisory Service (DART).
Investment Risk Notice: This content is provided for informational and language reference purposes only. Under no circumstances does it constitute financial advice or a recommendation to buy or sell any specific stock. All investment decisions and financial responsibilities rest entirely with the investor.
Contact: For compliance inquiries or copyright requests, please contact ksb220805@gmail.com.
